Raymond James Financial’s SAB Biotherapeutics SABS Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$37.6K Buy
+11,869
New +$43.2K ﹤0.01% 5319
2025
Q3
– Sell
-45
Closed -$79 – 6418
2025
Q2
$79 Buy
+45
New +$74 ﹤0.01% 6857

Other funds holding SABS

Raymond James Financial's SABS Position: Q3 2026 in Review

Raymond James Financial opened a new position in SAB Biotherapeutics (SABS) in Q3 2026: 11,869 shares worth $37.6K. The stake represents ﹤0.01% of the portfolio and ranks #5319 among its holdings. This is a return to the name: Raymond James Financial previously reported a position in SABS as recently as Q2 2025.

Raymond James Financial first reported a position in SABS in Q2 2025 and has held it in 2 quarters since. 102 funds tracked by Wall St. Rank hold SABS as of Q3 2026.

  • Raymond James Financial held 11,869 shares of SAB Biotherapeutics worth $37.6K as of Q3 2026.
  • SAB Biotherapeutics was a new Raymond James Financial position in Q3 2026.
  • SAB Biotherapeutics made up ﹤0.01% of Raymond James Financial's portfolio in Q3 2026, its #5319 holding.
  • Raymond James Financial first reported a position in SAB Biotherapeutics in Q2 2025 and has held it in 2 quarters since.
  • 102 funds tracked by Wall St. Rank held SAB Biotherapeutics as of Q3 2026.

Based on Raymond James Financial's 13F filing for Q3 2026, filed 12 Nov 2026.